Osteonecrosis of the jaw associated with receiving sunitinib monotherapy: A rare caseOsteonecrosis of the jawSunitinib monotherapyBisphosphonatesDenosumabSunitinib is an antiangiogenic drug for the treatment of metastatic renal cell carcinoma (mRCC) and imatinib-resistant gastrointestinal stromal tumor (GIST)....
Osteonecrosis of the jaw (ONJ) is a serious adverse drug event that was initially reported with intravenous bisphosphonates (BPs) and more recently with other classes of drugs such as receptor activator of NF-κB ligand (RANKL) inhibitor, antiangiogenic agents, and mammalian target of rapamycin ...
Osteonecrosis of the jaw (ONJ), also known as “dead jaw syndrome,” Avascular Necrosis and Aseptic Necrosis, is a rare but serious condition involving severe loss or destruction of the jawbone. ONJ disrupts the blood supply to the jawbone. This causes tiny breaks that can lead to total bo...
It is well established that alterations in phosphate metabolism have a profound effect on hard and soft tissues of the oral cavity. The present-day clinical form of osteonecrosis of the jaw (ONJ) was preceded by phosphorus necrosis of the jaw, ca. 1860.
It is likely that ONJ results from direct drug toxicity to cells of bone and soft tissue. The bone in ONJ lesions does not appear to be 'frozen' but rather there is very active bone resorption taking place, which is likely to be responsible for the local release at high concentrations ...
SummaryWith the increasing use of intravenous bisphosphonates in oncological settings, osteonecrosis of the jaw is now a more common and often devastating complication which, in an advanced stage, significantly impacts the quality of life. Since management and therapy of osteonecrosis present major challe...
In this review, the accepted recommendations for dental clearance prior to head and neck chemo-radiation therapy are put forth as a means of possibly preventing and treating drug induced ONJ. 展开 关键词: Osteonecrosis Bisphosphonates Antiresorptives Antiangiogenics Dental clearance Aging population ...
Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw 2018, Current Osteoporosis Reports Zoledronate Impairs Socket Healing after Extraction of Teeth with Experimental Periodontitis 2018, Journal of Dental Research Elevation of pro-inflammatory cytokine levels following anti-resorptive drug tr...
Antiresorptive drug-related osteonecrosis of the jaw. J Uyanne,Colonya C. Calhoun,Anh D. Le - Elsevier 被引量: 10发表: 2014年 Antiresorptive drug-related osteonecrosis of the jaw-an update Antiresorptive drug-related osteonecrosis of the jaw still poses major challenges for both patients and ...
Introduction: Medication-related osteonecrosis of the jaw (MRONJ) is a severely debilitating condition of multifactorial pathogenesis. It primarily involves patients receiving intravenous bisphosphonates (BPs) and most recently the new antiresorptive drug, denosumab, for the treatment of skeletal-related mal...